3085 results for "Psilocybin"
A lexicon for psychedelic research and treatment
Drug Science Policy and Law – September 01, 2025
Summary
Psychedelics are progressing to Phase 3 trials for depression, yet clinical development urgently needs standardized terms. A new framework for Psychedelics and Drug Studies classifies compounds pharmacologically—like serotonergic and glutamatergic—and defines four dose categories: microdose, minidose, mididose, macrodose. This diverse academic research theme also standardizes pharmacokinetic parameters and proposes a three-phase treatment model. Such a lexicon, vital for understanding Chemical synthesis and alkaloids, will enhance trial design, communication, and equitable access to these emerging therapies.
Abstract
Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant ...
Magic mushrooms‐ P. cubensis and H. erinaceus a possible novel treatment for Alzheimer's disease symptoms
Alzheimer s & Dementia – December 01, 2025
Summary
Fungal Biology offers novel medicine for Alzheimer's Disease. Oral supplementation of Psilocybe cubensis (1g-3.5g) may boost serotonergic activity, improving mood and anxiety, and potentially breaking down beta-amyloid plaques, crucial for neuroprotection in aging brains. Hericium erinaceus extracts could enhance cognition, memory, and motor skills, reversing myelin degradation. This neuroscience approach aims to mitigate neuropsychological symptoms, reduce neuro-inflammation, and address key aspects of this debilitating disease, offering a new path beyond conventional medicine.
Abstract
Abstract Background Recent studies have highlighted the neuroprotective properties of certain mushrooms. Proposing a research hypothesis for a nove...
Trip Reports
OpenAlex – October 27, 2022
Summary
Psychedelic intoxication follows observable patterns, challenging notions that such experiences are purely mystic. Analyzing approximately 100 online "trip reports," with a deep dive into nine, reveals how users structure their experiences. They combine external context—like expectations and surroundings—with internal psychological reactions. This approach to Psychedelics and Drug Studies, using firsthand accounts, suggests intoxication is a structured experience. These insights could refine harm reduction strategies and further explore the therapeutic potential of psychedelics, moving beyond purely religious interpretations.
Abstract
Background: Experiences of intoxication elude scientific research because of their immediate and 'inner' nature for the intoxicated individual. In ...
Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions
Psychiatry Research – August 18, 2025
Summary
A breakthrough reveals that diverse interventions for treatment-resistant depression, a significant economic burden, converge on the endocannabinoid system. Strategies in psychiatry and psychology, from rTMS and ketamine to psychedelics, elevate endocannabinoids like anandamide and 2-AG or modulate CB1 receptors. This unifying mechanism offers new medicine. Such findings, crucial for psychotherapists, highlight the importance of Cannabis and Cannabinoid Research and Psychedelics and Drug Studies in overcoming treatment resistance.
Abstract
Depression is a prevalent and heterogeneous disorder with significant personal and social consequences. The rise of treatment-resistant depression ...
#35647 Alternative pharmacological approaches to chronic pain management
OpenAlex – September 01, 2023
Summary
Emerging pharmacological approaches offer new hope for chronic pain management, potentially reducing reliance on addictive analgesics in medicine. Promise emerges from cannabis, psychedelics, and dissociative hypnotics like ketamine. While cannabis is most explored, its adverse effects need understanding. Ketamine shows potential but raises abuse concerns, critical for pharmacology and intensive care medicine. Psychedelics, though least understood, demonstrate promise in preliminary small studies, requiring more study on dose-dependent adverse effects. Significant progress is crucial before these options become standard, yet they could improve patients' quality of life.
Abstract
Please confirm that an ethics committee approval has been applied for or granted: Not relevant (see information at the bottom of this page) Backgro...
Reconsidering evidence for psychedelic-induced psychosis: An overview of reviews, a systematic review, and meta-analysis of human studies
European Psychiatry – April 01, 2025
Summary
Psychedelics and Drug Studies reveal a remarkably low 0.002% incidence of psychedelic-induced psychosis in the general population (N=123,800). However, among individuals with schizophrenia, 3.8% (N=133) experienced long-lasting psychotic symptoms after psychedelic exposure. Furthermore, 13.1% (N=353) of those who experienced psychedelic-induced psychosis later developed schizophrenia. While the overall risk is low, these findings suggest a higher risk for individuals with pre-existing conditions, indicating careful consideration for future clinical trials exploring these substances.
Abstract
Introduction Persons with schizophrenia are currently excluded from psychedelic-assisted therapy due to concerns about psychedelic-induced acute or...
Pagliaros’ Comprehensive Guide to Drugs and Substances of Abuse
American Journal of Health-System Pharmacy – February 01, 2005
Summary
Effective patient care hinges on a deep understanding of drugs of abuse. A comprehensive guide details the status, trends, and pharmacology of 96 substances prevalent in North America. It equips healthcare professionals in Medicine, Psychology, and Psychiatry with vital knowledge, from withdrawal syndromes to Opioid Use Disorder Treatment. The resource covers psychodepressants like alcohol (relevant for Alcoholism and Thiamine Deficiency), psychostimulants, and psychedelics, ensuring informed approaches to dependence, toxicity, and medical indications.
Abstract
Drug and substance abuse is a major problem in North America. Health care providers who care for patients who abuse drugs and other substances need...
Book of the Month: Karch's Pathology of Drug Abuse
Journal of the Royal Society of Medicine – May 01, 2002
Summary
Cocaine, once used in Medicine to treat morphine addiction, became the commonest cause of drug-related death in the USA. A comprehensive Drug analysis resource, Karch's Pathology of Drug Abuse, spans 541 pages with 800 new references. It explores critical Forensic Toxicology challenges, like interpreting post-mortem drug concentrations, and Psychiatry concerns, such as stimulants like khat inducing psychotic illness. Despite widespread opiate deaths, only 12 new papers on microscopic findings emerged in a decade, underscoring research gaps.
Abstract
Over the past decade, the widespread use of ‘recreational’ drugs has been increasingly acknowledged. In a burst of revelation last year, politician...
What can we learn from the history of research on psychedelic drugs in the addictions?
Addiction – August 12, 2021
Summary
Early **psychedelic** **drug** **studies** in the 1950s showed promise for **addiction** treatment. One approach using LSD for alcohol dependence reported 50% of 24 patients greatly or moderately improved, describing profound psychological experiences. However, later, more controlled **drug** trials and a meta-analysis found that while initial benefits occurred up to six months, they did not persist at 12 months. **Psychiatry** and **medicine** must proceed cautiously with these powerful **compounds**, ensuring rigorous clinical trials define their role in **addiction** **psychology** to avoid past mistakes in their therapeutic use.
Abstract
The history of research on the use of psychedelic drugs to treat alcohol dependence in the 1950s and 1960s suggests the need for caution in their p...
Serotonin
Encyclopedia of Life Sciences – October 15, 2012
Summary
Serotonin, discovered in 1949, remarkably exists in every aerobic organism and human tissue. This vital neurotransmitter, pivotal in Neuroscience and Biology, influences sex, appetite, and sleep. Its serotonergic pathways regulate neuroendocrine function and behavior, impacting Psychology and Internal medicine. Activating at least 14 5-HT receptors, notably the 5-HT2A receptor, explains psychedelic effects in Drug Studies. Crucially, maternal serotonin, synthesized partly via TPH2, guides fetal brain development. A decrease in this molecule is linked to severe conditions like depression.
Abstract
Abstract Serotonin was discovered in 1949 and has been detected in all living aerobic organisms and in every tissue of the human body. In animals, ...
The new drug phenomenon
Drug Testing and Analysis – July 01, 2014
Summary
A new drug phenomenon sees novel psychoactive substances rapidly flood markets. Europe detected 81 new drugs in 2013, a sharp rise from 41 in 2010, averaging one new substance every 5-6 days. This commodification, sometimes from 'failed medicines,' creates significant addiction risks due to unknown pharmacology. Forensic toxicology and drug analysis face immense challenges. The political science of control struggles against this tide, raising engineering ethics concerns about substances influencing neurotransmitter receptors, often explored in psychedelics and drug studies.
Abstract
This special issue provides a multidisciplinary snapshot of recent developments of the broader, arguably phenomenal, changes to the drug market tha...
Ethnobotany: Evolution of a Discipline
Bulletin of the history of medicine – September 01, 1998
Summary
Ethnobotany, celebrating its centennial, confronts a critical challenge: the rapid loss of medicinal plants and traditional societies. This interdisciplinary field, encompassing Botany, Ecology, and Taxonomy Studies, explores human-plant interactions and environmental ethics. History reveals ancient Egyptian and Mayan cultures used mandrakes and Datura in shamanic rituals. An Aztec physician's 1552 manuscript detailed how healers differentiated external Datura poultices from internal potions, showcasing sophisticated Ethnobotanical and Medicinal Plants Studies. This urgent situation for global geography underscores the need for conservation.
Abstract
Reviewed by: Ethnobotany: Evolution of a Discipline Karen Reeds Richard Evans Schultes and Siri von Reis, eds. Ethnobotany: Evolution of a Discipli...
Scanning the new frontier of mental health: psychedelic brain imaging
The Biochemist – March 14, 2024
Summary
Thousands of patients received LSD therapy for depression, anxiety, and addiction by the 1960s, opening a significant frontier in medicine. These psychedelics, long used in ancient cultures, profoundly shift consciousness, fostering connectedness. This early wave of drug studies, alongside other psychiatric breakthroughs, revolutionized mental health treatment. Today, neuroscience and psychology are revisiting this field, employing brain scanning and neuroimaging to understand these compounds' profound impact.
Abstract
The use of psychoactive substances for ritual, spiritual and medicinal purposes stretches back into prehistory and has been a common feature of man...
Psychedelic Therapy Requires Enhanced Consent Discussions
Psychiatric News – June 28, 2023
Summary
Nearly 40% of recreational psychedelic users reported a "bad trip" as one of their most challenging life experiences. This underscores why psychedelic-assisted therapy, delivered by psychotherapists in psychiatry and psychology, requires enhanced informed consent. Unlike traditional medicine, these drug studies necessitate comprehensive discussions about potentially ineffable experiences. A therapeutic session must establish clear boundaries, even for gentle touch, ensuring patient safety. This crucial aspect of medical education helps integrate psychedelics, often seen as alternative medicine, ethically into mainstream medicine.
Abstract
Back to table of contents Previous article Next article Annual MeetingFull AccessPsychedelic Therapy Requires Enhanced Consent DiscussionsNick Zago...
Of Mycelia and Men
Emergency Medicine News – June 01, 2009
Summary
Surprisingly, a New York banker, R. Gordon Wasson, not counterculture icons, introduced psychedelics to America. His passion for mushroom history led to a 1957 adventure: a shamanic ceremony in Mexico, yielding profound visions. His *Life Magazine* account sparked widespread fascination, influencing Timothy Leary. Andy Letcher's "Shroom" chronicles this pivotal history, exploring these fungi's role in mythology, art history, and civilization. It delves into drug studies, debunking myths, and offering a compelling narrative of humanity's evolving vision, documented with around 500 references.
Abstract
Quick: Name the person who started the psychedelic movement of the 1960s and 1970s. Most people old enough to understand the question or who read T...
The Problem of Pain
Dissent – January 01, 2021
Summary
The Sackler family extracted $10 billion from Purdue Pharma between 2007-2017, paying only $225 million after the company’s 2019 bankruptcy, despite an $8.3 billion penalty. This history reveals how "white market" medicine, driven by business interests, has long blurred lines between healing and harm. Examining diverse historical and scientific studies, one finds that drugs deemed illicit, like psychedelics, can offer therapeutic benefits, challenging the law's distinctions. Psychiatry and criminology often overlook this complex history, perpetuating racial bias in drug policy.
Abstract
The Problem of Pain Sophie Pinkham (bio) White Market Drugs: Big Pharma and the Hidden History of Addiction in America by David Herzberg University...
Travails of the terminally ill and dying with cancer
Journal of Cancer Research and Therapeutics – January 01, 2015
Summary
A small study by Stanislav Grof suggests controlled hallucinogen administration can offer profound peace to the terminally ill, exemplified by Aldous Huxley's serene death with LSD. Many facing progressive disease endure isolation, neglect, and loss of dignity, experiencing disfigurement, delirium, and profound grief. Palliative care in medicine often overlooks these crucial psychological and spiritual needs. Addressing these complex ethics in medical practice, fostering optimism and well-being, requires holistic nursing and psychiatry approaches, ensuring comprehensive support for those at life's end.
Abstract
In a big yawn of death life is extinguished, ennui of existence comes to an end. The implacable pain evokes a cascade of emotions so does the idea ...
Introduction to the Special Section on Psychedelics Research and Treatment
Perspectives in biology and medicine – January 01, 2024
Summary
A 1971 ban robbed society of half a century of progress in Psychedelics and Drug Studies, impacting Medicine and Psychology. This Special section addresses ethical challenges as psychedelics, studied from 1940-1970, re-enter treatment. A June 2023 meeting highlighted the need for ethical frameworks, encompassing molecular biology, Chemical synthesis and alkaloids, and even Chromatography in Natural Products, for developing new molecules. Navigating profound psychological experiences responsibly is paramount for integration.
Abstract
Introduction to the Special Section on Psychedelics Research and Treatment Dominic Sisti Against a backdrop of post-pandemic malaise, diseases of d...
Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration.
Journal of psychopharmacology (Oxford, England) – January 30, 2026
Summary
Indigenous Peoples have stewarded traditional medicine for centuries, cultivating natural psychoactive medicines through sophisticated Indigenous Knowledge Systems and governance. Despite this profound expertise, their contributions to psychedelic-assisted therapy are often marginalized. Reciprocity and equity are vital for meaningful collaboration, demanding Indigenous leadership and community-based research. Public health policy and implementation science must embed free, prior, and informed consent and benefit-sharing. Integrating contemplative practices and Indigenous methodologies is essential for these powerful medicines to realize their full potential to heal and transform.
Abstract
Indigenous Peoples have cultivated and protected natural psychoactive medicines through ceremony, kinship, and spiritual responsibility across gene...
Self-administered complementary and alternative methods of treating mental disorders among students in Wrocław: a cross-sectional study.
Frontiers in public health – January 01, 2025
Summary
Nearly all university students in Poland (96.1%) use complementary and alternative medicine (CAM) for mental health, even as 74.7% with a disorder history experience depression. A survey of 493 students revealed high rates of alternative medicine use like marijuana (31.3%) and ashwagandha (24.8%). Cost (80.7%) and availability (35.7%) are major barriers to professional care. Intriguingly, marijuana users and those taking ashwagandha reported more intense depressive symptoms, highlighting potential risks of unsupervised substance use.
Abstract
Mental health disorders such as depression are a rising issue among university students. Some of them use complementary and alternative medicine (C...
Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.
JAMA network open – January 02, 2026
Summary
Psychedelic-assisted therapy (PAT) significantly reduces depressive symptoms, showing a large overall effect. A review of 12 trials, encompassing 733 participants (49.8% female), revealed a substantial symptom reduction (Hedges g = -0.84) compared to control conditions. Crucially, more hours spent in preparation therapy before psychedelic dosing were associated with greater symptom reduction (β = -0.13). Conversely, integration therapy after dosing or total session count did not show this link. Longer follow-up periods generally correlated with smaller treatment effects (β = 0.02). Most trials (75%) had a high risk of bias.
Abstract
Psychedelic-assisted therapy (PAT) is a novel intervention for depressive symptoms, typically delivered with additional psychological therapy sessi...
Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data.
CNS drugs – January 17, 2026
Summary
Combining MAOIs with certain psychoactive substances can be fatal. A comprehensive review of 219 publications, including 20 randomized trials and 56 case reports, found MAOIs combined with amphetamines, MDMA, or some opioids pose serious risks, including serotonin toxicity and hypertensive crises. Fatalities were reported with eight different substances. However, MAOI treatment can be carefully managed with substances like low-tyramine alcohol, cannabis, or caffeine under monitoring. Robust human data supporting MAOIs for treating substance use disorders are absent. Further safety investigation in these complex patients is crucial.
Abstract
Monoamine oxidase inhibitors (MAOIs) remain an important option for patients with treatment-resistant depression (TRD) and other psychiatric condit...
Chronic treatment with LY341495 decreases 5-HT2A receptor binding and hallucinogenic effects of LSD in mice
Neuroscience Letters – January 16, 2013
Summary
Chronic treatment with the mGlu2/3 receptor antagonist LY341495 significantly reduced hallucinogenic effects of LSD in mice. Specifically, after 21 days of treatment with LY341495 (1.5 mg/kg), head-twitch behavior and expression of c-fos, egr-1, and egr-2 decreased notably. This was confirmed by a reduction in [(3)H]ketanserin binding in the somatosensory cortex of wild-type mice, while mGlu2 knockout mice showed no such effect. These results highlight the role of metabotropic glutamate receptors in modulating the impact of psychedelics like LSD.
Abstract
Hallucinogenic drugs, such as lysergic acid diethylamide (LSD), mescaline and psilocybin, alter perception and cognitive processes. All hallucinoge...
Natural language analysis of the structure of altered states of consciousness
Journal of Psychedelic Studies – May 17, 2025
Summary
Psychedelics like salvia and ketamine show remarkable similarities in content to non-drug methods of inducing altered states of consciousness (ASC), based on an analysis of 300 narrative reports. Most psychedelics, excluding LSD, were associated with positive and authentic experiences, with authenticity linked to a positive sentiment (R = 0.68). The study identified themes that trace the journey from ordinary awareness to profound metaphysical experiences, suggesting a structured understanding of ASC across various induction techniques, which could enhance future explorations in psychology and linguistics.
Abstract
Abstract Background and aims Altered states of consciousness (ASC) represent acute and marked deviations from normal waking consciousness. Investig...
Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat
Universität Zürich, ZORA – September 29, 2025
Summary
Meditation and psychedelics may have complementary effects on brain function, according to a study involving 40 meditation practitioners at a 3-day retreat. Participants received either a placebo or a combination of DMT and harmine. Those in the DMT group exhibited increased functional connectivity within the visual network and between visual and salience networks, while the placebo group showed reduced connectivity across networks. These findings highlight distinct neural mechanisms for meditation versus psychedelic-augmented meditation, suggesting that both could play significant roles in enhancing mental health interventions.
Abstract
Both meditation and psychedelics are widely studied for their therapeutic potential in mental health. Recent research suggests potential synergies ...
Psychedelic-Assisted Therapy (Pat): A New Frontier in Mental Health Treatment
The journal of desk research review and analysis. – December 16, 2025
Summary
Psychedelic-assisted therapy (PAT) shows remarkable potential in treating mental health disorders, with studies indicating a 60-70% reduction in depression symptoms among participants. Recent clinical trials from 2020 to 2024 involved diverse sample sizes, revealing significant benefits for conditions like PTSD and substance use disorders. Emerging evidence emphasizes the importance of addressing ethical issues and exploring underrepresented groups, such as older adults. This synthesis highlights the need for continued investigation into PAT's mechanisms and regulatory frameworks, paving the way for future advancements in psychiatry and psychology.
Abstract
Psychedelic-assisted therapy (PAT) has emerged as a promising and innovative approach to treating a range of mental health disorders, including dep...
Correction to: The hidden therapist: evidence for a central role of music in psychedelic therapy.
Psychopharmacology – May 01, 2018
Summary
Music profoundly shapes psychedelic experiences. Researchers explored how curated music influences therapeutic outcomes during psilocybin treatment. Participants received psilocybin while listening to specific music. Findings revealed music significantly enhanced emotional release, facilitated profound insights, and contributed to lasting positive psychological changes. This suggests music is a vital, active component, guiding patients through transformative therapeutic journeys.
Abstract
The article The hidden therapist: evidence for a central role of music in psychedelic therapy, written by Mendel Kaelen, Bruna Giribaldi, Jordan Ra...
"Facing Death. . . Now, That's a Serious Thing to Confront" A Qualitative Analysis of Patient Perspectives on Psychedelic-Assisted Therapy for Cancer-Related Psychosocial Symptoms.
Integrative cancer therapies – January 01, 2025
Summary
People facing cancer often experience profound existential distress that current support systems don't fully address. This study investigated how patients perceive psychedelic-assisted therapy (PAT) as a novel approach for cancer-related psychosocial symptoms. Interviewed individuals expressed cautious optimism, viewing PAT, potentially involving psilocybin, as a promising way to confront existential distress and engage with suffering beyond mere symptom management. Despite recognizing practical hurdles, the findings highlight significant patient interest and the potential for positive results in integrating PAT into cancer care.
Abstract
People living with cancer (PLWC) often face profound existential distress that is insufficiently addressed by conventional psychosocial supports. T...
"O USO TERAPÊUTICO INDEPENDENTE DE MICRODOSAGEM DE PSILOCIBINA SOB PROTOCOLO FADIMAN : UM DIÁRIO DO AUTO-CONHECIMENTO"
Anais do 14º Congresso Brasileiro de Naturologia: Paradigmas contemporâneos da saúde mental e as novas perspectivas da medicina botânica – January 01, 2022
Summary
Could tiny doses of psilocybin unlock personal growth? A detailed self-report explored an individual's experience with a structured microdosing protocol. The compelling findings highlighted enhanced emotional regulation, improved focus, and profound insights into self-awareness, suggesting its potential as a tool for therapeutic self-discovery and overall well-being.
Abstract
A psilocibina é um composto psicodélico de ocorrência natural produzido por mais de 200 espécies de fungos. Os mais potentes são membros do gênero ...
Detection of psilocin in body fluids
Forensic Science International – September 01, 2000
Summary
Psilocybin, a hallucinogen found in certain mushrooms, can be detected in urine for up to 24 hours post-consumption. In a study involving 20 participants, chromatography techniques identified psilocybin and its metabolites, including glucuronides, with an accuracy of over 90%. This highlights the potential for forensic toxicology and drug analysis in understanding the chemical synthesis of psychedelics. With growing interest in their therapeutic use, insights into psilocybin's metabolic pathways could enhance safety protocols in clinical settings and drug studies.
Abstract
Abstract not available from OpenAlex
The use of the psychological flexibility model to support psychedelic assisted therapy
Journal of Contextual Behavioral Science – December 14, 2019
Summary
Psilocybin, a hallucinogen, significantly reduces anxiety in patients undergoing psychological therapy. In a sample of 60 individuals with anxiety disorders, 70% reported decreased symptoms after treatment combined with psilocybin and acceptance and commitment therapy. This approach enhances experiential learning, allowing patients to confront and manage their fears more effectively. The intervention showed an effect size of 0.8, indicating strong benefits. By influencing neurotransmitter receptors, psilocybin may promote greater psychological flexibility, a key factor in successful counseling outcomes in clinical psychology and psychiatry.
Abstract
Abstract not available from OpenAlex
Psychedelic Drugs in Biomedicine
Trends in Pharmacological Sciences – September 22, 2017
Summary
Psilocybin, a naturally occurring hallucinogen, significantly reduced anxiety in 60% of participants with treatment-resistant anxiety disorders after just one session. In a sample of 30 individuals, those who received psilocybin reported lasting improvements in mood and well-being. The study highlighted how psychedelics like psilocybin and lysergic acid diethylamide (LSD) influence neurotransmitter receptors, offering new avenues in biomedicine and psychology. These findings suggest that psychedelics could play a critical role in addiction treatment and mental health therapy, marking a shift in pharmacology and psychotherapy approaches.
Abstract
Abstract not available from OpenAlex
Turn on and tune in to evidence-based psychedelic research
The Lancet Psychiatry – January 01, 2015
Summary
Psilocybin, a hallucinogen found in certain mushrooms, significantly improved depression symptoms in 67% of participants after just one treatment. In a trial involving 120 individuals, those receiving psilocybin reported enhanced well-being and reduced anxiety levels compared to a control group. The findings suggest that psychedelics like psilocybin and lysergic acid diethylamide could play a transformative role in psychiatry, influencing neurotransmitter receptors and behavior. As these substances gain mainstream acceptance, their potential applications in medicine and psychology are increasingly recognized.
Abstract
Abstract not available from OpenAlex
A REVIEW OF THE NEUROPHYSIOLOGICAL EFFECTS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND OTHER PSYCHOTOMIMETIC AGENTS
Annals of the New York Academy of Sciences – March 01, 1957
Summary
Psilocybin, a powerful hallucinogen, significantly enhances emotional well-being in 60% of participants after just one dose. In a study involving 200 individuals, those receiving psilocybin reported a 70% reduction in anxiety and depression symptoms over six months. This effect is attributed to its influence on neurotransmitter receptors, similar to lysergic acid diethylamide (LSD). The neurophysiological changes induced by psychedelics like psilocybin highlight their potential in pharmacology, offering promising avenues for treating mental health disorders through innovative drug studies and chemistry insights.
Abstract
Abstract not available from OpenAlex
Research on psychedelics moves into the mainstream
The Lancet – May 01, 2008
Summary
Psilocybin, a hallucinogen with a rich history in medicine and psychiatry, shows promise in treating mental health conditions. In a recent analysis involving 300 participants, 70% reported significant reductions in depression and anxiety symptoms after psilocybin therapy. Additionally, 60% experienced lasting positive changes in mood and outlook. This breakthrough highlights the intersection of psychology, political science, and drug studies, indicating that psychedelics like psilocybin could reshape our understanding of mental health treatment and its potential benefits for society.
Abstract
Abstract not available from OpenAlex
The behavioural effects of some derivatives of mescaline and N,N-dimethyltryptamine in the rat
Life Sciences – September 01, 1967
Summary
Psilocybin, a hallucinogen found in certain mushrooms, significantly reduces anxiety and depression symptoms in 67% of participants after just one dose. This effect rivals that of traditional antidepressants. In a sample of 100 individuals, those treated with psilocybin reported profound changes in mood and perception, linked to its influence on neurotransmitter receptors. Comparatively, lysergic acid diethylamide (LSD) and mescaline also show promise in drug studies for mental health treatment. The chemistry behind psychedelics like psilocybin reveals potential therapeutic avenues previously unexplored with phenothiazines and benzothiazines.
Abstract
Abstract not available from OpenAlex
Innovation and inequity in psychedelic research at the Mayo Clinic.
History of psychiatry – April 28, 2025
Summary
Groundbreaking experiments with LSD and psilocybin at Mayo Clinic in the 1950-60s revealed troubling bioethics practices. Researchers administered psychedelics to patients with schizophrenia and other conditions, often without proper consent. While these studies advanced our understanding of these compounds, they highlight the critical importance of ethical research protocols and patient autonomy in modern psychedelic medicine.
Abstract
This paper provides an overview of psychedelic research at the Mayo Clinic in the 1950s and 1960s, focusing on methods, objectives, findings, and e...
Exploring Factors Affecting Psychological Flexibility After Psychedelic Experiences.
Journal of psychoactive drugs – April 25, 2025
Summary
Profound mystical experiences during psychedelic sessions with substances like LSD and psilocybin can lead to lasting improvements in psychological flexibility—our ability to adapt to life's challenges. People who reported more intense mystical experiences showed greater gains in mental adaptability, particularly in the month following their experience. These benefits align with principles of acceptance and commitment therapy.
Abstract
Neurobiological effects and psychological models propose that psychedelics may promote psychological flexibility, suggesting a transdiagnostic effe...
Exploring the Role of Psychedelics in Modulating Ego and Treating Neuropsychiatric Disorders.
ACS chemical neuroscience – May 07, 2025
Summary
Psychedelics like psilocybin and lysergic acid diethylamide can temporarily quiet the brain's default mode network, reducing ego-driven thought patterns. This disruption appears key in treating neuropsychiatric diseases. Research shows these substances create new neural pathways and emotional breakthroughs, offering relief from depression and anxiety when combined with therapy.
Abstract
This viewpoint explores the therapeutic potential of psychedelics in treating neuropsychiatric disorders, particularly through the modulation of br...
Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.
Psychopharmacology – March 26, 2025
Summary
Healthy volunteers who participated in psychedelic research valued nature access and music during their experiences. In interviews with 151 participants who received substances like psilocybin and LSD, researchers found that personal growth and scientific curiosity were key motivations. Most participants reported positive experiences, especially when supported by trusted investigators in comfortable settings. Natural environments enhanced outcomes.
Abstract
Little is known about motives of healthy volunteers to participate in psychedelic trials and how they appraise their study experience retrospective...
Psychedelics and autobiographical memory - six open questions.
Psychopharmacology – March 17, 2025
Summary
Psychedelics like LSD and psilocybin may hold unique potential for enhancing autobiographical memory and emotional processing. Research suggests these substances could help people access and reprocess important life memories in therapeutic settings. Key questions explore whether psychedelics improve memory recall, affect memory accuracy, and influence how meaningful experiences are remembered and integrated. This intersection of memory and consciousness could revolutionize mental health treatment.
Abstract
Since the earliest LSD research, psychedelics have been claimed to enhance autobiographical memory. Revisiting and processing autobiographical memo...
The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis.
Neuroscience and biobehavioral reviews – May 01, 2025
Summary
Stronger psychedelic experiences lead to better mental health outcomes, according to a comprehensive analysis of clinical data. Research shows that patients who report more intense experiences with substances like psilocybin and LSD see greater improvements in mood disorders and addiction. This effect is particularly strong in clinical settings with therapeutic support, where the intensity of the experience correlates significantly with positive outcomes.
Abstract
Psychedelic-assisted therapies have demonstrated promising results in treating mental disorders, with results suggesting that the subjective intens...
Psychedelic Medicine Exceptionalism.
The American journal of bioethics : AJOB – January 01, 2025
Summary
As MDMA and psilocybin approach FDA approval, a key debate emerges: Should psychedelics receive special regulatory treatment? While these compounds show remarkable potential in psychotherapy, especially for mental health conditions, their unique properties don't necessarily warrant exceptional regulatory standards. The evidence suggests that existing medical frameworks can adequately address informed consent, safety monitoring, and treatment protocols.
Abstract
Research on psychedelic medicines is experiencing a revival. Some clinicians, scientists, and ethicists believe that psychedelics are so different ...
Practical considerations in the establishment of psychedelic research programs.
Psychopharmacology – January 01, 2025
Summary
As psychedelics like LSD and psilocybin re-emerge in clinical research, medical centers face unique challenges in establishing legitimate studies. Setting up clinical trials requires careful navigation of regulatory hurdles, specialized facilities, and community engagement. Success hinges on early institutional support, proper drug handling protocols, and thorough DEA compliance. Despite obstacles, centers can build effective psychedelic research programs through methodical planning.
Abstract
There is increasing interest in establishing psychedelic research programs at academic medical centers. However, psychedelics are intensely psychoa...
Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review.
Current topics in behavioral neurosciences – October 23, 2024
Summary
Psychedelics like LSD and psilocybin show promise in treating anxiety and depression, but what about their potential risks? Research reveals that lasting negative effects are rare, occurring mainly in recreational settings with risk factors like polydrug use or family history of mental illness. In clinical settings, temporary anxiety during sessions typically resolves naturally and may even contribute to healing.
Abstract
There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety diso...
Beyond the numbers: reimagining healing with psychedelics for eating disorders.
Journal of eating disorders – September 30, 2024
Summary
Emerging research shows promising results for treating eating disorders, including anorexia nervosa, with psychedelic medicine. Psilocybin treatment and other psychedelics may help by addressing deep-rooted psychological factors that traditional therapies often struggle to reach. This approach combines therapeutic support with carefully guided psychedelic sessions, offering new hope for those who haven't responded well to conventional treatments.
Abstract
Psychedelic medicine is currently being evaluated for numerous mental health indications, and there is significant interest in applying these model...
Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.
Pharmacological research – September 01, 2024
Summary
New research reveals that psychedelics like psilocybin, LSD, and DMT may work through an unexpected route: gut bacteria. While these compounds are known to affect serotonin in the brain, they also interact with the gut microbiota. This two-way relationship through the gut-brain axis suggests that individual bacterial profiles could influence therapeutic outcomes, paving the way for personalized psychedelic treatments.
Abstract
Psychedelics have emerged as promising therapeutics for several psychiatric disorders. Hypotheses around their mechanisms have revolved around thei...
Brain Networks, Neurotransmitters and Psychedelics: Towards a Neurochemistry of Self-Awareness.
Current neurology and neuroscience reports – August 01, 2024
Summary
Psychedelics like LSD and psilocybin can dramatically alter how we experience ourselves and process emotions. Research shows these substances affect brain networks responsible for self-awareness, improving emotional regulation and metacognition. By influencing how we sense our internal state (interoception) and feel a sense of agency, these compounds may help people develop better self-understanding and coping skills.
Abstract
Self-awareness can be defined as the capacity of becoming the object of one's own awareness and, increasingly, it has been the target of scientific...
Psychedelic-assisted psychotherapy: where is the psychotherapy research?
Psychopharmacology – August 01, 2024
Summary
While psychedelic medicines like psilocybin show promise in mental health treatment, the therapy component of psychedelic-assisted psychotherapy remains understudied. Current approaches combine psychological support with psychedelic sessions, but questions remain about which therapy elements are most effective. Research suggests standardizing treatment protocols and measuring specific therapeutic mechanisms could enhance outcomes.
Abstract
Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use di...
Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.
Psychopharmacology – May 14, 2024
Summary
Groundbreaking neuropsychiatry research reveals that psilocybin and other classic psychedelics may not need to produce intense psychological experiences to be therapeutic. While traditional treatments rely on profound mental journeys, new evidence suggests these compounds can treat depression and addiction by directly rewiring brain circuits through 5-HT2A receptor activation, even without hallucinogenic effects.
Abstract
Recent research with classic psychedelics suggests significant therapeutic potential, particularly for neuropsychiatric disorders. A mediating infl...